- Home
- OTLK vs OPTN Comparison
OTLK vs OPTN Comparison
Compare OTLK & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- OPTN
- Stock Information
- Founded
- OTLK 2010
- OPTN 2010
- Country
- OTLK United States
- OPTN United States
- Employees
- OTLK N/A
- OPTN N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- OPTN Health Care
- Exchange
- OTLK Nasdaq
- OPTN Nasdaq
- Market Cap
- OTLK 121.8M
- OPTN 99.7M
- IPO Year
- OTLK 2016
- OPTN 2017
- Fundamental
- Price
- OTLK $5.03
- OPTN $0.48
- Analyst Decision
- OTLK Strong Buy
- OPTN Strong Buy
- Analyst Count
- OTLK 7
- OPTN 3
- Target Price
- OTLK $48.20
- OPTN $3.00
- AVG Volume (30 Days)
- OTLK 243.0K
- OPTN 1.2M
- Earning Date
- OTLK 12-20-2024
- OPTN 11-12-2024
- Dividend Yield
- OTLK N/A
- OPTN N/A
- EPS Growth
- OTLK N/A
- OPTN N/A
- EPS
- OTLK N/A
- OPTN N/A
- Revenue
- OTLK N/A
- OPTN $75,672,000.00
- Revenue This Year
- OTLK N/A
- OPTN $24.44
- Revenue Next Year
- OTLK N/A
- OPTN $49.00
- P/E Ratio
- OTLK N/A
- OPTN N/A
- Revenue Growth
- OTLK N/A
- OPTN 5.13
- 52 Week Low
- OTLK $4.61
- OPTN $0.32
- 52 Week High
- OTLK $12.85
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- OTLK 35.70
- OPTN 39.22
- Support Level
- OTLK $5.03
- OPTN $0.32
- Resistance Level
- OTLK $5.44
- OPTN $0.46
- Average True Range (ATR)
- OTLK 0.37
- OPTN 0.08
- MACD
- OTLK -0.12
- OPTN -0.02
- Stochastic Oscillator
- OTLK 2.01
- OPTN 33.19
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.